JP2020500930A5 - - Google Patents

Info

Publication number

JP2020500930A5

JP2020500930A5 JP2019547795A JP2019547795A JP2020500930A5 JP 2020500930 A5 JP2020500930 A5 JP 2020500930A5 JP 2019547795 A JP2019547795 A JP 2019547795A JP 2019547795 A JP2019547795 A JP 2019547795A JP 2020500930 A5 JP2020500930 A5 JP 2020500930A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

pharmaceutically acceptable

composition according

patient

bez235

Prior art date

2017-11-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000003839 salts Chemical class 0.000 claims description 48
• 238000000034 method Methods 0.000 claims description 38
• JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 29
• 229950006418 dactolisib Drugs 0.000 claims description 29
• 201000010099 disease Diseases 0.000 claims description 11
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
• 206010057190 Respiratory tract infections Diseases 0.000 claims description 7
• 230000002159 abnormal effect Effects 0.000 claims description 5
• 108090000623 proteins and genes Proteins 0.000 claims description 5
• 102000014150 Interferons Human genes 0.000 claims description 3
• 108010050904 Interferons Proteins 0.000 claims description 3
• 230000001939 inductive effect Effects 0.000 claims description 3
• 229940079322 interferon Drugs 0.000 claims description 3
• 238000009097 single-agent therapy Methods 0.000 claims description 3
• 239000000427 antigen Substances 0.000 claims description 2
• 102000036639 antigens Human genes 0.000 claims description 2
• 108091007433 antigens Proteins 0.000 claims description 2
• 230000028993 immune response Effects 0.000 claims description 2
• 230000036039 immunity Effects 0.000 claims description 2
• 230000015788 innate immune response Effects 0.000 claims description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical class CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 22
• 208000020029 respiratory tract infectious disease Diseases 0.000 claims 3
• 239000003814 drug Substances 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 206010062106 Respiratory tract infection viral Diseases 0.000 claims 1
• 208000020017 viral respiratory tract infection Diseases 0.000 claims 1
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 14
• 229960005167 everolimus Drugs 0.000 description 14
• 208000015181 infectious disease Diseases 0.000 description 11
• 208000035473 Communicable disease Diseases 0.000 description 8
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 5
• 230000032683 aging Effects 0.000 description 5
• 210000002744 extracellular matrix Anatomy 0.000 description 5
• 238000007634 remodeling Methods 0.000 description 5
• 230000004064 dysfunction Effects 0.000 description 4
• 206010019280 Heart failures Diseases 0.000 description 3
• 208000019425 cirrhosis of liver Diseases 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 208000033679 diabetic kidney disease Diseases 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• 208000001076 sarcopenia Diseases 0.000 description 2
• 210000002435 tendon Anatomy 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• 206010058314 Dysplasia Diseases 0.000 description 1
• 206010019668 Hepatic fibrosis Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 230000009759 skin aging Effects 0.000 description 1
• 208000019206 urinary tract infection Diseases 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1